Genetic Polymorphisms and Drug Interactions Leading to Clopidogrel Resistance: Why the Asian Population Requires Special Attention

REFERENCES

• Gerald F. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clin Res ed.). 2002;324:71–86.
   PubMedGoogle Scholar
• Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45: 1157–64.
   PubMedGoogle Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.
   PubMedGoogle Scholar
• Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120:311–21.
   PubMedGoogle Scholar
• Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ. 2012;21:12–21.
   PubMedGoogle Scholar
• Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992–1000.
   PubMedGoogle Scholar
• Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets. 2008;19:595–604.
   PubMedGoogle Scholar
• Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630–6.
   PubMedGoogle Scholar
• Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849–56.
   PubMedGoogle Scholar
• Xie H-G, Zou J-J, Hu Z-Y, Zhang J-J, Ye F, Chen S-L. Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther. 2011;129:267–89.
   PubMedGoogle Scholar
• Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost. 2007;98:707–9.
   PubMedGoogle Scholar
• Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon M-C, Hurbin F, Sultan E. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost. 2011;105:696–705.
   PubMedGoogle Scholar
• Huber K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur Heart J. 2010;31:2974–6.
   PubMedGoogle Scholar
• Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486–501.
   PubMedGoogle Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.
   PubMedGoogle Scholar
• Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–8.
   PubMedGoogle Scholar
• Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van ‘t Hof AWJ, Ruven HJT, Hackeng CM, Klungel OH, de Boer A, Deneer VHM. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010;31:3046–53.
   PubMedGoogle Scholar
• FDA US Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm203888.htm
   Google Scholar
• Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56:321–41.
   PubMedGoogle Scholar
• Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–58.
   PubMedGoogle Scholar
• Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy. 2010;30:265–74.
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.
   PubMedGoogle Scholar
• Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot J-S, Kastrati A, Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–30.
   PubMedGoogle Scholar
• Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J-S, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328–32.
   PubMedGoogle Scholar
• Holmes DR Jr., Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation. 2010;122:537–57.
   PubMedGoogle Scholar
• Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J, Johnson JA. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328–32.
   PubMedGoogle Scholar
• Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011;78:243–57.
   PubMedGoogle Scholar
• Bauer T, Bouman HJJ, van Werkum JWW, Ford NFF, ten Berg JMM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
   PubMed Web of Science ®Google Scholar
• Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306:2704–14.
   PubMedGoogle Scholar
• Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307:1482–5.
   Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.
   PubMedGoogle Scholar
• Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128:307–16.
   PubMedGoogle Scholar
• Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166–71.
   PubMedGoogle Scholar
• Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429–36.
   PubMedGoogle Scholar
• Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010;20:18–25.
   PubMedGoogle Scholar
• Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz H-G, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110–6.
   PubMedGoogle Scholar
• Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Shen H, Tanner K, Horenstein RB, Pakzy R, Tantry US, Bliden KP, Gurbel PA, Shuldiner AR. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther. 2011;90:568–74.
   PubMedGoogle Scholar
• Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann F-J. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circulation. Cardiovasc Genet. 2011; 4:429–36.
   PubMedGoogle Scholar
• Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32:1605–13.
   PubMedGoogle Scholar
• Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, Degorter MK, Woolsey S, Tirona RG, Kim RB. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J. 2012. [Epub ahead of print]. doi: 10.1093/eurheartj/ehs042.
   Google Scholar
• Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009;133:341–5.
   PubMedGoogle Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Barrera-Ramirez C, Sabaté M, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005;115:101–8.
   PubMedGoogle Scholar
• Bonello L, Bonello-Palot N, Armero S, Bonello C, Mokhtar OA, Arques S, Dignat-George F, Camoin-Jau L, Paganelli F. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res. 2010;125:e167–70.
   PubMedGoogle Scholar
• Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174:1715–22.
   PubMedGoogle Scholar
• Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2002;107:32–7.
   Google Scholar
• Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483–94.
   PubMedGoogle Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 52:1557–63.
   PubMedGoogle Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart (British Cardiac Society). 2010; 96:186–9.
   PubMedGoogle Scholar
• Bates ER, Lau WC, Angiolillo DJ: Clopidogrel-drug interactions. J Am Coll Cardiol. 2011; 57:1251–63.
   PubMedGoogle Scholar
• Sibbing D, Beckerath NVV, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Scho A, Kastrati A, von Beckerath N, Schömig A. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010;31:1205–11.
   PubMedGoogle Scholar
• Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120:188–92.
   PubMedGoogle Scholar
• Siller-Matula JM, Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. Evid Based Med. 2011;16:144–5.
   PubMedGoogle Scholar
• Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall J-F, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–60.
   PubMedGoogle Scholar
• Mistry SD, Trivedi HR, Parmar DM, Dalvi PS, Jiyo C. Impact of proton pump inhibitors on efficacy of clopidogrel: review of evidence. Indian J Pharmacol. 2011;43:183–6.
   PubMedGoogle Scholar
• Kwan J, Htun WW, Huang Y, Ko W, Kwan TW. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. Vasc Health and Risk Manag. 2011;7:399–404.
   PubMedGoogle Scholar
• Tran M, Tafreshi J, Pai RG. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. JCardiovasc Pharmacol Ther. 2010;15:326–37.
   PubMedGoogle Scholar
• Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006;3:387–95.
   PubMedGoogle Scholar
• Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–34.
   PubMedGoogle Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–5.
   PubMedGoogle Scholar
• Guha S, Mookerjee S, Guha P, Sardar P, Deb S, Roy PD, Karmakar R, Mani S, Hema MB, Pyne S, Chakraborti P, Deb PK, Lahiri P, Chaudhuri U. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. Indian Heart J. 2009;61: 348–52.
   PubMedGoogle Scholar
• Aradi D, Komócsi A. Platelet function monitoring in patients on clopidogrel: what should we learn from GRAVITAS? Platelets. 2012;23:167–76.
   PubMedGoogle Scholar
• Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420–5.
   PubMedGoogle Scholar
• Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221–8.
   PubMedGoogle Scholar
• Trenk D, Hochholzer W, Fromm MF, Chialda L-E, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn H-P, Büttner HJ, Neumann F-J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925–34.
   PubMedGoogle Scholar
• Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.
   PubMed Web of Science ®Google Scholar
• Ong TZ, Raymond AA. Risk factors for stroke and predictors of one-month mortality. Singapore Med J. 2002;43:517–21.
   PubMedGoogle Scholar
• Delcourt C, Hackett M, Wu Y, Huang Y, Wang J, Wong L, Sun J, Li Q, Wei JW, Liu M, Li Z, Cheng Y, Huang Q, Xu E, Yang Q, Lu C, Craig S. Determinants of quality of life after stroke in China: the China QUEST (QUality Evaluation of Stroke care and Treatment) study. Stroke. 2011;42:433–8.
   PubMed Web of Science ®Google Scholar
• Venketasubramanian N, Tan LCS, Sahadevan S, Chin JJ, Krishnamoorthy ES, Hong CY, Saw SM. Prevalence of stroke among Chinese, Malay, and Indian Singaporeans: a community-based tri-racial cross-sectional survey. Stroke. 2005;36:551–6.
   PubMedGoogle Scholar
• Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess (Winchester, England). 2011;15:1–178.
   Google Scholar
• Luk HH, Pang J, Li LSW, Ng M. Use of antiplatelet drugs in the stroke unit of a Hong Kong hospital. Pharm World Sci. 2005;27:258–62.
   Google Scholar
• Uchiyama S, Fukuuchi Y, Yamaguchi T. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two phase III, multicenter, randomized clinical trials. J Neurol. 2009;256:888–97.
   PubMedGoogle Scholar
• Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart. 2011;98:139–44.
   PubMedGoogle Scholar
• Kim KA, Park PW, Hong SJ, Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236–42.
   PubMedGoogle Scholar
• Lee JM, Park S, Shin D-J, Choi D, Shim CY, Ko Y-G, Kim J-S, Shin E-S, Chang CW, Lee J-E, Jang Y. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol. 2009;104:46–51.
   PubMedGoogle Scholar
• Kim I-S, Jeong Y-H, Park Y, Park K-S, Yun S-E, Park J-R, Hwang S-J, Koh E-H, Kwak CH, Hwang J-Y, Kim S. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011;4:381–91.
   PubMedGoogle Scholar
• Park KJ, Chung HS, Kim SR, Kim HJ, Han JY, Lee SY. Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med. 2011;31:91–4.
   PubMedGoogle Scholar
• Park KW, Kang J, Park JJ, Yang H-M, Lee H-Y, Kang H-J, Koo B-K, Oh B-H, Park Y-B, Kim H-S. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart (British Cardiac Society). 2012;98: e1366–72.
   Google Scholar
• Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, Ikeda T, Yamamoto H, Akao M, Furukawa Y, Shizuta S, Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishimoto N, Ouchi C, Morimoto T, Kita T, Kimura T. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J. 2009;73:336–42.
   PubMedGoogle Scholar
• Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008;6:1439–41.
   PubMedGoogle Scholar
• Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida a, Kobayashi T, Hosohata K, Ushijima K, Fujimura A. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther. 2011;89:229–33.
   PubMedGoogle Scholar
• Kumar S, Saran RK, Puri A, Gupta N, Sethi R, Surin WR, Dikshit M, Dwivedi SK, Narain VS, Puri VK. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. Indian Heart J. 2007;59:152–6.
   PubMedGoogle Scholar
• Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P, Deb PK, Chaudhuri U, Deb S, Karmakar R, Dasgupta AK, Lahiri P. Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart J. 2009;61:68–73.
   PubMedGoogle Scholar
• Wang L, Wang X, Chen F. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs in R & D. 2010;10:219–24.
   Google Scholar
• Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705–9.
   PubMedGoogle Scholar
• Luo Y, Zhao YT, Verdo A, Qi WG, Zhang DF, Hu B. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res. 2011;39:2012–9.
   PubMedGoogle Scholar
• Cave W, Pandey P, Chatterjee S. Irrational prescribing in South Asia: a case of fluoroquinolone-associated phototoxicity. J Travel Med. 2003;10:290–2.
   PubMedGoogle Scholar
• Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Am J Cardiol. 2000;36:699–705.
   Google Scholar
• Vallurupalli NG, Goldhaber SZ. Gastrointestinal complications of dual antiplatelet therapy. Circulation. 2006;113:e655–8.
   PubMedGoogle Scholar
• Seddighzadeh A, Wolf AT, Parasuraman S, Shetty R, Vallurupalli N, Reddy S, Goldhaber SZ. Gastrointestinal complications after 3 months of dual antiplatelet therapy for drug-eluting stents as assessed by wireless capsule endoscopy. Clin Appl Thromb Hemost. 2009;15:171–6.
   PubMedGoogle Scholar
• Rogacka R, Chieffo A, Michev I, Airoldi F, Latib A, Cosgrave J, Montorfano M, Carlino M, Sangiorgi GM, Castelli A, Godino C, Magni V, Aranzulla TC, Romagnoli E, Colombo A. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv. 2008;1:56–61.
   PubMedGoogle Scholar
• Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep. 2011;38:1697–702.
   PubMedGoogle Scholar
• Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306: 1215–23.
   PubMedGoogle Scholar
• Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H, Kozuki A, Inoue T, Hariki H, Hirata K. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J. 2010;75:99–105.
   PubMedGoogle Scholar
• Wang X, Zhang D, Zhuang S, Lai Y. Clinical investigation modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol. 2011;34:332–8.
   PubMedGoogle Scholar
• Aradi D, Vorobcsuk A, Komócsi A. Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account? J Am Coll Cardiol. 2008;52:1349; author reply 1349-50.
   PubMedGoogle Scholar
• Cuisset T, Frere C, Quilici J, Alessi MC, Bonnet JL. Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late? J Am Coll Cardiol. 2008;52:790–1; author reply 791-2.
   Google Scholar
• Fu Q, Suzuki N, Takada K. Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 * 2 /* 2 genotype. Cardiovasc Interv Ther. 2010;26:79–82.
   PubMedGoogle Scholar
• Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486–501.
   PubMedGoogle Scholar